December 10th & 11th, 2026
10th edition
MARSEILLE, FR

miRoncol Health

Stand C49

2025 Edition

miRoncol Health

Canada

miRoncol Health will launch the first-of-its-kind microRNA based mutli-cancer risk stratification blood test in 2026. The proof of concept studies demonstrated superior performance particularly for early stage cancers with ~90% sensitivity at 99%+ specificity among ~80% common solid tumors other than breast cancer. It outperforms mainstream ctDNA based tests and is also more affordable due to requiring only a few microRNAs and using widely available PCR technology.

Before you leave…

Download the official MedFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of MedFIT 2026.